Grifols falls on report Brookfield delays offer on funding issues
Grifols (NASDAQ:GRFS) dropped 3% after a report that Brookfield (BAM) is delaying a takeover bid due to issues raising money ...
Brookfield still pursuing Grifols deal, Bloomberg reports
EST Brookfield still pursuing Grifols (GRFS) deal, Bloomberg reports Published first on TheFly – the ultimate source for ...
pharmaphorum6d
Could Spain’s Grifols be heading for de-listing?
The family that owns Spanish drugmaker Grifols and private equity firm Brookfield are considering whether to take the company private in a deal that could be worth around €5.5 billion (almost $6 ...
The Corner8d
Brookfield fund delays Grifols takeover bid for second time after failing to raise required €10,000 million
Brookfield fund has failed to raise the nearly €10,000 million needed to acquire 70% of the company and restructure the debt.
akm8d
Brookfield plans to acquire Spanish blood plasma manufacturer Grifols
Brookfield Asset Management is in talks with several investment funds as part of the proposed acquisition of the Spanish blood plasma company Grifols SA. This is reported in a Brookfield press ...
Yahoo Finance13d
Grifols, S.A. (GIFLF)
Canadian fund Brookfield reaffirmed its interest in a potential takeover of Spanish drugmaker Grifols and requested more time to complete due diligence for its possible bid, two sources with ...
ETF Daily News5d
Grifols (NASDAQ:GRFS) Raised to Strong-Buy at Berenberg Bank
The company has a 50 day moving average of $8.82 and a 200 day moving average of $7.77. Grifols has a twelve month low of $5.30 and a twelve month high of $12.15. Get Grifols alerts: Grifols ...
New Atlas10d
World-first treatment to prevent long-term eye damage from mustard gas
Global healthcare company Grifols has partnered with BARDA, the Biomedical Advanced Research and Development Authority, to develop the first immune therapy eye drops to prevent the long-term ...